A photochemical approach for controlled drug release in targeted drug delivery.

Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Bioorganic & medicinal chemistry (Impact Factor: 2.82). 02/2012; 20(3):1281-90. DOI: 10.1016/j.bmc.2011.12.020
Source: PubMed

ABSTRACT Photochemistry provides a unique mechanism that enables the active control of drug release in cancer-targeting drug delivery. This study investigates the light-mediated release of methotrexate, an anticancer drug, using a photocleavable linker strategy based on o-nitrobenzyl protection. We evaluated two types of the o-nitrobenzyl-linked methotrexate for the drug release study and further extended the study to a fifth-generation poly(amidoamine) dendrimer carrier covalently conjugated with methotrexate via the o-nitrobenzyl linker. We performed the drug release studies by using a combination of three standard analytical methods that include UV/vis spectrometry, (1)H NMR spectroscopy, and anal. HPLC. This article reports that methotrexate is released by the photochemical mechanism in an actively controlled manner. The rate of the drug release varies in response to multiple control parameters, including linker design, light wavelength, exposure time, and the pH of the medium where the drug release occurs.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This aim of this study was to develop peptide-conjugated nanoparticles (NPs) for systemic co-delivery of siRNA and doxorubicin to enhance chemotherapy in epidermal growth factor receptor (EGFR) high-expressed ovarian tumor bearing mice. The active targeting NPs were prepared using heptapeptide-conjugated poly(d,l-lactic-co-glycolic acid)–poly(ethylene glycol). The particle sizes of peptide-free and peptide-conjugated NPs were 159.3 ± 32.5 and 184.0 ± 52.9 nm, respectively, with zeta potential −21.3 ± 3.8 and −15.3 ± 2.8 mV. The peptide-conjugated NPs uptake were more efficient in EGFR high-expressed SKOV3 cells than in EGFR low-expressed HepG2 cells due to heptapeptide specificity. The NPs were used to deliver small molecule anticancer drug (e.g., doxorubicin) and large molecule genetic agent (e.g., siRNA). The IC50 of doxorubicin-loaded peptide-conjugated NPs (0.09 ± 0.06 μM) was significantly lower than peptide-free NPs (5.72 ± 2.64 μM). The similar result was observed in siRNA-loaded NPs. The peptide-conjugated NPs not only served as a nanocarrier to efficiently deliver doxorubicin and siRNA to EGFR high-expressed ovarian cancer cells but also increased the intracellular accumulation of the therapeutic agents to induce assured anti-tumor growth effect in vivo.
    Journal of Nanoparticle Research 10/2013; 15(10). · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of novel tetrahydro-4H-pyrano[3,2-c]pyridines(3a–3p) were synthesized and found to possess potent antiproliferative activity against leukemia K562 cells in vitro. Preliminary bioassay indicates that compounds 3a and 3e afford the best activity, the IC50 values of them were 6.93 and 7.51 μg/mL, respectively, which were lower than that of the anticancer drug 5-FU(IC50=8.56 μg/mL). To reduce the toxicity of compounds 3a–3p to the proliferation of normal hematopoietic cells, a tumor targeted CD14 monoclonal antibody(McAb) was used in conjugation with compounds 3a–3p to get conjugates 4a–4p, respectively. The inhibitory activities of conjugates 4a–4p toward K562 cells were discovered to approach those of compounds 3a–3p. In the presence of CD14 McAb, tumor cells were found to be much more susceptible to conjugates 3a–3p than normal hematopoietic cells. Therefore, the toxicity of conjugates 4a–4p to normal hematopoietic cells declined obviously. For example, as for the toxicity of compound 3a compared with that of compound 4a, the value of IC50 increased from 35.90 μmol/L to 39.52 μmol/L.
    Chemical Research in Chinese Universities 12/2013; 29(6):1104-1109. · 1.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review reports some recent advances on the use of dendrimers as a versatile platform for targeted drug delivery applications. The unique 3-dimensional architectures and macromolecular characteristics afford dendrimers with ideal drug delivery ability through encapsulating drugs in their interior or covalently conjugating drugs on their surfaces. The adaptable surface functionalization ability enables covalent conjugation of various targeting molecules onto the surface of dendrimers, thereby allowing for generation of various multifunctional nanodevices for targeted drug delivery applications. In particular, the application of dendrimers as versatile platforms for targeted cancer therapeutics will be introduced in detail.
    J. Mater. Chem. B. 08/2013; 1(34).

Full-text (2 Sources)

Available from
Jun 4, 2014